Xtandi for parotid cancer – pro
Androgen deprivation therapy has some clinical activity in selected salivary gland cancer histotypes, with androgen receptor expression. There are several small studies but more is needed to elucidate the mechanism of responses and the dose and how to use this drug.
There is an ongoing trial: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers, ClinicalTrials.gov Identifier: NCT02749903
Dalin MG, Watson PA, Ho AL, Morris LG. Androgen Receptor Signaling in Salivary Gland Cancer. Cancers (Basel). 2017;9(2):17.
Locati LD et al, Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Head Neck. 2016 May;38(5):724-31.